Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Enzymatica AB's Pre-Tax Income for the
three
months ended in Mar. 2026 was €-1.24 Mil. Enzymatica AB's Revenue for the
three
months ended in Mar. 2026 was €1.06 Mil. Therefore, Enzymatica AB's pretax margin for the quarter that ended in Mar. 2026 was -116.48%.
The historical rank and industry rank for Enzymatica AB's Pretax Margin % or its related term are showing as below:
STU:EN9'
s Pretax Margin % Range Over the Past 10 Years
Min: -140.45 Med: -88.18 Max: -11.74
Current: -88.45
STU:EN9's Pretax Margin % is ranked worse than 90.25% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs STU:EN9: -88.45
Enzymatica AB (STU:EN9) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Enzymatica AB Pretax Margin % Related Terms
Enzymatica AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Enzymatica AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzymatica AB Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Enzymatica AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzymatica AB (STU:EN9) has a Pretax Margin % of -116.48% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Enzymatica AB and its competitors. According to the industry distribution chart, Enzymatica AB ranks #861 out of 954 companies in the Drug Manufacturers industry, placing it in the top 90.3%.
Is Enzymatica AB's Pretax Margin % too high?
Enzymatica AB's current Pretax Margin % is -116.48%. Based on the distribution chart, Enzymatica AB ranks #861 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enzymatica AB has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enzymatica AB ranks #861 out of 954 companies for Pretax Margin %. This places Enzymatica AB in the lower half of its industry. The industry median Pretax Margin % is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Enzymatica AB and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current Pretax Margin % is -116.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Enzymatica AB (STU:EN9) has a current Pretax Margin % of -116.48%. The stock's GF Value™ is €0.16, compared to a current price of €0.18 — trading 14.4% above its estimated fair value. The current Pretax Margin % is -116.48%. Enzymatica AB's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Enzymatica AB (STU:EN9), the current Pretax Margin % is -116.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (STU:EN9) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued.
The current stock price of €0.18 is trading 14.4% above its estimated GF Value™ of €0.16.
Key valuation signals for STU:EN9:
Pretax Margin %: -116.48%
GF Value™: €0.16 vs. price of €0.18 (14.4% above fair value)
No single metric tells the full story. See the STU:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
58GF Score
Get the complete analysis for STU:EN9
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EN9 has been successfully added to your 
